E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers G > Headlines for Genomic Health, Inc. > News item
Published on 11/3/2006 in the Prospect News Biotech Daily.

Genomic Health kept at outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Genomic Health, Inc. at market outperform as Genomic Health's third quarter exceeded expectations, pointing to strong Oncotype DX adoption. Duncan augmented the price target to $21.00 from $19.00. Shares of the Redwood City, Calif.-based biotechnology company were down 12 cents, or 0.78%, at $15.31. (Nasdaq: GHDX)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.